Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04458532Recruiting
Exercise program to boost heart health after early breast cancer
This trial studies whether a structured exercise program can improve cardiovascular (heart and blood vessel) health in post-menopausal women after early-stage breast cancer treatment. It specifically targets women who have trouble with exercise and have completed cancer treatment within the last 1 to 5 years.
Hartford, ConnecticutAges 21–80 - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT07264790RecruitingPhase 1
Minoxidil for Better Blood Flow in Breast Reconstruction
This trial tests whether applying minoxidil (a hair growth medication) to breast tissue during surgery can improve blood flow to the reconstructed breast. It is for women who are having both breasts removed to prevent cancer and have reconstruction on the same day.
Durham, North CarolinaAges 18 years+ - NCT06718933RecruitingPhase 1/Phase 2
Study of a drug combination for breast cancer that spread to the brain
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT07320664Recruiting
Alcohol and Breast Cancer Risk in Young Women
This study looks at how drinking alcohol affects young women's understanding of breast cancer risk. It involves answering questions and possibly wearing a sensor to track drinking.
Columbus, OhioAges 18–25 - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT06958991Recruiting
Laser scanner test during breast cancer surgery
This trial tests a new laser scanner that helps doctors see if all cancer cells are removed during breast-conserving surgery, which might reduce the need for a second operation.
Villars-sûr-glâne, Canton of FribourgAges 18 years+ - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT07358182Recruiting
Trastuzumab-rezetecan for breast cancer with HER2 protein
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+ - NCT07743827Recruiting
Olanzapine-based steroid-sparing anti-nausea treatment for breast cancer
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
Alexandria, Alexandria GovernorateAges 18–70 - NCT06922708Recruiting
Using genetic risk scores to improve breast cancer prevention
This study is testing a new way to use your genetic information (along with your family history) to better understand your personal risk for breast cancer. The goal is to see if giving this risk report to women with higher genetic risk can help them and their doctors make more informed decisions about screening and prevention.
RomaAges 18–79 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT04360330Recruiting
MRI study in early breast cancer with specific lab markers
This study tests selected treatment decisions for women with early-stage breast cancer that has certain lab test results. It may help researchers better match care using MRI and tumor marker information.
Miami, FloridaAges 50 years+ - NCT07734389Recruiting
Genetic breast cancer risk test for DORA study participants
This trial offers genetic testing to women who took part in the earlier DORA study and were found to have a moderately increased or high risk of breast cancer. It aims to better understand genetic risk factors to improve early detection and prevention.
LjubljanaAges 53–54 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-negative breast cancer
This trial tests a new drug called Dato-DXd for people with a specific type of breast cancer that is hormone receptor-positive and HER2-negative (IHC 0). It's for those whose cancer has stopped responding to hormone therapy and who haven't had chemotherapy for cancer that has spread.
Largo, FloridaAges 18 years+ - NCT07120087Recruiting
Online program to lower breast cancer risk for high-risk women
This trial tests an online program that teaches women at high risk of breast cancer how to lower their risk. If you were part of the MyPeBS study and found to have high risk, this program might help you take steps to protect your health.
LyonAges 40–74 - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 741 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.